Nitroxyl Technology

Cardioxyl has developed industry leading expertise in nitroxyl (HNO) chemistry and biology, and is employing its nitroxyl chemistry platform to discover and develop novel, proprietary therapeutics targeting cardiovascular disease.
Read More

HNO Clinical Studies

Having demonstrated human proof of concept with its first generation compound, Cardioxyl is advancing its improved second-generation HNO donor, CXL-1427, into the clinic for the potential treatment of ADHF. The HNO donor candidate is currently in Phase II clinical testing.
Read More